According to insider reports, Pfizer is exploring the sale of its hospital medicines division. The pharmaceutical giant has engaged Goldman Sachs to gauge initial interest from potential buyers, including private equity firms and other pharmaceutical companies.
While this move indicates Pfizer's strategic evaluation of its business segments, insiders emphasize that the sale is not yet certain, and Pfizer may ultimately decide to retain the unit. Both Pfizer and Goldman Sachs declined to comment on these developments.
